Why the study?
Managing antithrombotic therapy in patients with atrial fibrillation undergoing PCI for coronary artery disease remains challenging due to concurrent indications for oral anticoagulation and antiplatelet therapy, requiring balance of thromboembolic and bleeding risks.
Does dual antithrombotic therapy reduce bleeding compared to triple therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?
Does dual antithrombotic therapy reduce bleeding compared to triple therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?
In patients with atrial fibrillation undergoing PCI, dual antithrombotic therapy (OAC plus a P2Y12 inhibitor) is increasingly preferred over traditional triple therapy due to a significant reduction in bleeding risk without compromising ischemic outcomes.
Optimal regimen in AF-PCI patients remains uncertain; leaves open questions on balancing thromboembolic and bleeding risks.
The management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary artery disease remains a challenge in clinical practice. This group of patients has indications for both oral anticoagulation and antiplatelet therapy. Such combination will require careful considerations of both thromboembolic and bleeding risks. There have been several big trials looking at the rationale of treating those patients with an oral anticoagulant in combination with one (dual-therapy strategy) or two antiplatelet agents (triple-therapy strategy).
No takes yet. Share an insight, caveat, or question.
Alkindi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: